OncoHost Achieves Prestigious Recognition at the 2025 BIG Innovation Awards

OncoHost Achieves Prestigious Recognition at the 2025 BIG Innovation Awards



OncoHost, a trailblazer in precision oncology, recently received the esteemed 2025 BIG Innovation Award in the Healthcare category. This accolade, granted by the Business Intelligence Group, highlights OncoHost's commitment to enhancing personalized cancer therapy through innovative approaches.

Russ Fordyce, the CEO of the Business Intelligence Group, emphasized, "Humanity relies on innovation to improve our lives and the planet. We're thrilled to spotlight OncoHost as a shining example of innovation making a profound impact globally."

At the core of OncoHost's success is its cutting-edge platform, PROphet®, which addresses the significant challenge of identifying effective biomarkers. The inadequacy of clear biomarkers has often left clinicians without the necessary guidance for immunotherapy treatments, resulting in suboptimal patient responses. Despite the multitude of clinical trials investigating immunotherapy options, the quest for actionable biomarkers has been notably slow. PROphet® seeks to fill this critical void by providing insights that help tailor immunotherapy strategies, thereby enhancing patient outcomes.

The initial commercial offering of the platform, named PROphetNSCLC™, stands out as the first liquid biopsy proteomics test available and is recognized as the inaugural AI-based blood test designed to assist in first-line immunotherapy decisions for metastatic non-small cell lung cancer (NSCLC). Its initial validation in NSCLC has paved the way for broader applications; PROphet® also shows potential in assessing benefits for patients with melanoma, renal cell carcinoma (RCC), HPV-related cancers, triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), as well as colorectal cancer. This versatility suggests the viability of the plasma-proteomics signature across various malignancies, highlighting the expansive utility of OncoHost’s innovative technology.

Moreover, OncoHost continues to advance patient care through the development of the PROphetirAE test, which aims to predict immune-related adverse events before patient treatment initiation. By identifying individuals at higher risk of experiencing severe side effects, this model fosters improved patient management and informed treatment decisions, a crucial factor in oncology care.

Expressing pride in the achievements, Dr. Ofer Sharon, CEO of OncoHost, stated, "We are honored to receive this prestigious recognition alongside remarkable innovators shaping the future through bold ideas. This achievement reflects the passion, expertise, and dedication of our team as we push the boundaries of science to deliver impactful solutions. It reaffirms our commitment to advancing oncology and driving meaningful progress in healthcare innovation as we move into 2025."

Organizations worldwide submitted their latest innovations for the BIG Innovation Awards, evaluated by a panel of experienced business leaders. These judges took into account creativity, measurable results, and overall impact when selecting winners, further solidifying OncoHost’s position as a leader in precision oncology.

About OncoHost


Based in Binyamina, Israel, and Cary, North Carolina, OncoHost is a commercial-stage precision oncology company committed to transforming the landscape of cancer treatment. Comprised of a skilled team of seasoned entrepreneurs and industry experts, OncoHost is conducting extensive clinical trials across over 40 sites globally. With a focus on understanding patient-specific responses to therapies, the organization aims to overcome one of oncology's most significant challenges: treatment resistance. Leveraging strong clinical evidence, intellectual property advantages, and a pioneering spirit, OncoHost’s PROphet® platform utilizes proteomic pattern recognition, bioinformatics, and AI technologies to bolster oncologists' clinical decision-making processes.

For further details, please visit OncoHost's website or follow the company on social media platforms such as LinkedIn, X, and Facebook.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.